TRIL Trillium Therapeutics

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients with advanced relapsed or refractory lymphoma.

Presentation details are as follows:

Presenter: Krish Patel, MD

Title: Ongoing, First-in-human, Phase 1 Dose Escalation Study of the Investigational CD47-blocker TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma

Session: Developmental Therapeutics - Immunotherapy

Abstract: 3030

Session Type: Poster Presentation (Poster #94)

The poster will be available on the meeting website beginning Friday, May 29 at 8:00 am ET. A copy of the poster will also be available on the Events and Presentations page of Trillium’s website.

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system.

For more information visit:

Company Contact:

James Parsons

Chief Financial Officer

Trillium Therapeutics Inc.

416-595-0627 x232



Media Relations:

Mike Beyer

Sam Brown Inc.

312-961-2502

EN
13/05/2020

Underlying

TRILTrillium Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trillium Therapeutics

Free Trial
TRIL Trillium Therap...

Troubadour Resources Inc: 1 director

A director at Troubadour Resources Inc sold 1,226,800 shares at 0.050CAD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

TRIL TRILLIUM THERAPEUTICS
10/26/23 October 26, 2023 1 EN
 PRESS RELEASE
Free
TRIL Trillium Therap...

Trillium Therapeutics Receives Final Court Order Approving Arrangement

Trillium Therapeutics Receives Final Court Order Approving Arrangement CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the “Arrangement”) with PF Argentum ULC (“PF Argentum”), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”). Pur...

October 28, 2021 1 EN
 PRESS RELEASE
Free
TRIL Trillium Therap...

Trillium Securityholders Approve Acquisition by Pfizer

Trillium Securityholders Approve Acquisition by Pfizer CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the i...

October 26, 2021 1 EN
Free Trial
TRIL Trillium Therap...

TRILLIUM THERAPEUTICS sees a downgrade to Negative on account of less ...

The independent financial analyst theScreener just lowered the general evaluation of TRILLIUM THERAPEUTICS (CA), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date October 19, 2021, the closing price was CAD 21.86 and its targe...

TRIL TRILLIUM THERAPEUTICS
10/20/21 October 20, 2021 6 EN
 PRESS RELEASE
Free
TRIL Trillium Therap...

Pfizer to Acquire Trillium Therapeutics Inc.

Pfizer to Acquire Trillium Therapeutics Inc. Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives NEW YORK and CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into ...

August 23, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch